<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    7053190
   </pmid>
   <datecreated>
    <year>
     1980
    </year>
    <month>
     03
    </month>
    <day>
     24
    </day>
   </datecreated>
   <datecompleted>
    <year>
     1980
    </year>
    <month>
     03
    </month>
    <day>
     24
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2004
    </year>
    <month>
     11
    </month>
    <day>
     17
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Print">
      0016-5085
     </issn>
     <journalissue citedmedium="Print">
      <volume>
       78
      </volume>
      <issue>
       3
      </issue>
      <pubdate>
       <year>
        1980
       </year>
       <month>
        Mar
       </month>
      </pubdate>
     </journalissue>
     <title>
      Gastroenterology
     </title>
     <isoabbreviation>
      Gastroenterology
     </isoabbreviation>
    </journal>
    <articletitle>
     Symptomatic relapse after oral vancomycin therapy of antibiotic-associated pseudomembranous colitis.
    </articletitle>
    <pagination>
     <medlinepgn>
      431-4
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext>
      Twenty patients with antimicrobiol-associated diarrhea had a symptomatic relapse after oral vancomycin therapy. All patients had stool examinations which implicated C. difficile as the causative agent, and 16 had pseudomembranous colitis. Clinical courses were characterized by resolution of symptoms with recurrence of diarrhea at 4--21 days after vancomycin was discontinued. Studies of stools collected sequentially showed that vancomycin failed to eliminate C. difficile despite susceptibility to this agent with in vitro testing. A review of our records shows the incidence os symptomatic relapse is approximately 14%. This experience emphasizes the importance of adequate follow-up in patients treated with oral vancomycin for antibiotic-associated diarrhea or colitis due to C. difficile.
     </abstracttext>
    </abstract>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Bartlett
      </lastname>
      <forename>
       J G
      </forename>
      <initials>
       JG
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Tedesco
      </lastname>
      <forename>
       F J
      </forename>
      <initials>
       FJ
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Shull
      </lastname>
      <forename>
       S
      </forename>
      <initials>
       S
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Lowe
      </lastname>
      <forename>
       B
      </forename>
      <initials>
       B
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Chang
      </lastname>
      <forename>
       T
      </forename>
      <initials>
       T
      </initials>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <publicationtypelist>
     <publicationtype>
      Journal Article
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     UNITED STATES
    </country>
    <medlineta>
     Gastroenterology
    </medlineta>
    <nlmuniqueid>
     0374630
    </nlmuniqueid>
    <issnlinking>
     0016-5085
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Anti-Bacterial Agents
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Cytotoxins
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      1404-90-6
     </registrynumber>
     <nameofsubstance>
      Vancomycin
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    AIM
   </citationsubset>
   <citationsubset>
    IM
   </citationsubset>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Anti-Bacterial Agents
     </descriptorname>
     <qualifiername majortopicyn="N">
      adverse effects
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Clostridium
     </descriptorname>
     <qualifiername majortopicyn="N">
      isolation &amp; purification
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Clostridium Infections
     </descriptorname>
     <qualifiername majortopicyn="Y">
      drug therapy
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Cytotoxins
     </descriptorname>
     <qualifiername majortopicyn="N">
      isolation &amp; purification
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Enterocolitis, Pseudomembranous
     </descriptorname>
     <qualifiername majortopicyn="N">
      chemically induced
     </qualifiername>
     <qualifiername majortopicyn="Y">
      drug therapy
     </qualifiername>
     <qualifiername majortopicyn="N">
      microbiology
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Follow-Up Studies
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Microbial Sensitivity Tests
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Recurrence
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Vancomycin
     </descriptorname>
     <qualifiername majortopicyn="Y">
      administration &amp; dosage
     </qualifiername>
    </meshheading>
   </meshheadinglist>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      1980
     </year>
     <month>
      3
     </month>
     <day>
      1
     </day>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      1980
     </year>
     <month>
      3
     </month>
     <day>
      1
     </day>
     <hour>
      0
     </hour>
     <minute>
      1
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      1980
     </year>
     <month>
      3
     </month>
     <day>
      1
     </day>
     <hour>
      0
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pubmed">
     7053190
    </articleid>
    <articleid idtype="pii">
     S0016508580000376
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

